HERSOL XXI, SL acquired an additional 0.6% stake in Pangaea Oncology, S.A. from director of Grupo Pikolin, S.L. for €0.15 million.
January 02, 2018
Share
HERSOL XXI, SL acquired an additional 0.6% stake in Pangaea Oncology, S.A. (BME:PANG) from director of Grupo Pikolin, S.L. for €0.15 million on December 29, 2017. HERSOL acquired 0.06 million shares of Pangaea Oncology at €2.34 per share. As a result of this transaction, director of Grupo Pikolin now owns 24.8% stake in Pangaea Oncology.
HERSOL XXI, SL completed the acquisition of an additional 0.6% stake in Pangaea Oncology, S.A. (BME:PANG) from director of Grupo Pikolin, S.L. on December 29, 2017.
Pangaea Oncology SA is a Spain-based company primarily engaged in the biotechnology sector. The Company focuses on the development of oncology treatments. The Companyâs activities are divided into two business lines: Clinical care in the Dr. Rosell Oncology Institute (IOR) and Molecular diagnosis (Dx). The IOR division offers personalized medical services related to oncology area, such as diagnosis, laboratory testing and treatment, in a chain of hospitals in Catalonia, Spain. The Dx division is responsible for the development of diagnostic and in-vitro services, biomarkers, as well as targeted drugs for patients and pharmaceutical companies. Its diagnostic models include Liquid Biopsy and Multiplexing.
PANGAEA ONCOLOGY, S.A. 